| Id: | acc2248 |
| Group: | 2sens |
| Protein: | RB1 |
| Gene Symbol: | RB1 |
| Protein Id: | P06400 |
| Protein Name: | RB_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr356 |
| Site Sequence: | SIDSFETQRTPRKSNLDEEVN |
| Disease Category: | Cancer |
| Disease: | Head and Neck Cancer |
| Disease Subtype: | HNSCC |
| Disease Cellline: | FaDu |
| Disease Info: | |
| Drug: | palbociclib(CDK4/6 inhibitors) |
| Drug Info: | "Palbociclib is a selective oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with endocrine therapies such as aromatase inhibitors or fulvestrant. " |
| Effect: | modulate |
| Effect Info: | The median survival time of tumor patients with low levels of pT356RB1 is almost four times that of patients with high pT356RB1 expression when they receive surgery or surgery plus radiotherapy. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 26265441 |
| Sentence Index: | 26265441_1-2 |
| Sentence: | "Locally advanced squamous cell carcinoma of the head and neck (SCCHN) that is not associated with human papillomavirus (HPV) has a poor prognosis in contrast to HPV-positive disease. To better understand the importance of RB1 activity in HPV-negative SCCHN, we investigated the prognostic value of inhibitory CDK4/6 phosphorylation of RB1 on threonine 356 (T356) in archival HPV-negative tumor specimens from patients who underwent surgical resection and adjuvant radiation." |
Sequence & Structure:
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| RB1-Thr356 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | -0.816 |
| HGSC | 0.881 |
| ccRCC | |
| GBM | -0.914 |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | 0.85 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 356 | U | Ovarian cancer/carcinoma | Phosphorylation | 28319064 |
| T | 356 | U | Squamous cell carcinoma | Phosphorylation | 26265441 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Staursporin | 6.3161 | down | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | A549 | Staursporin | 6.4743 | down | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | A549 | Dasatinib | 8.7153 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | K562 | Paclitaxel | 7.5238 | - | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | K562 | Paclitaxel | 8.7492 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Tideglusib | 7.7718 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Refametinib | 6.9355 | - | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | A549 | Refametinib | 8.7832 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Pictilisib | 5.7612 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | PD325901 | 9.0731 | - | |
| P06400 | RB1 | P | Thr356 | LFLDHDKTLQTDSIDSFETQRT(ph)PR | A549 | Nintedanib | 5.2492 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Dasatinib | 5.0787 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | Dasatinib | 7.2207 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Afatinib | 8.4298 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A549 | AZD8055 | 8.8775 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Gefitinib | 6.7699 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Gefitinib | 5.4291 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Gefitinib | 7.5513 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Gefitinib | 2 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Dasatinib | 6.0442 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Dasatinib | 2 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Dasatinib | 5.5741 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Dasatinib | 5.7699 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Afatinib | 8.6577 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Afatinib | 6.6511 | - | |
| P06400 | RB1 | P | Thr356 | TLQTDSIDSFETQRT(ph)PR | A431 | Afatinib | 2 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
